Literature DB >> 16978209

Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer.

M Lahn, P McClelland, D Ballard, K Mintze, D Thornton, G Sandusky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16978209     DOI： 10.1111/j.1365-2559.2006.02461.x

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


× No keyword cloud information.
  7 in total

1.  Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer.

Authors:  Karen-Lise Garm Spindler; Jan Lindebjerg; Michael Lahn; Sanne Kjaer-Frifeldt; Anders Jakobsen
Journal:  Int J Colorectal Dis       Date:  2009-03-10       Impact factor: 2.571

2.  Protein kinase C beta in malignant pleural mesothelioma.

Authors:  Leonardo Faoro; Sivakumar Loganathan; Maria Westerhoff; Rahul Modi; Aliya N Husain; Maria Tretiakova; Tanguy Seiwert; Hedy L Kindler; Everett E Vokes; Ravi Salgia
Journal:  Anticancer Drugs       Date:  2008-10       Impact factor: 2.248

3.  A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.

Authors:  Sukhmani K Padda; Yelena Krupitskaya; Laveena Chhatwani; George A Fisher; Alexander D Colevas; Melanie San Pedro-Salcedo; Rodney Decker; Jane E Latz; Heather A Wakelee
Journal:  Cancer Chemother Pharmacol       Date:  2011-12-11       Impact factor: 3.333

4.  Down-regulation of PKCζ in renal cell carcinoma and its clinicopathological implications.

Authors:  Yeong-Shiau Pu; Chao-Yuan Huang; Jyue-Yu Chen; Wang-Yi Kang; Ying-Chu Lin; Yu-Shiang Shiu; Shu-Ju Chuang; Hong-Jeng Yu; Ming-Kuen Lai; Yu-Chieh Tsai; Wen-Jeng Wu; Tzyh-Chyuan Hour
Journal:  J Biomed Sci       Date:  2012-04-05       Impact factor: 8.410

5.  Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells.

Authors:  Ola Al-Sanabra; Andrew D Duckworth; Mark A Glenn; Benjamin R B Brown; Piera Angelillo; Kelvin Lee; John Herbert; Francesco Falciani; Nagesh Kalakonda; Joseph R Slupsky
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

6.  Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.

Authors:  T Shimokawa; M Seike; C Soeno; H Uesaka; A Miyanaga; H Mizutani; K Kitamura; Y Minegishi; R Noro; T Okano; A Yoshimura; A Gemma
Journal:  Br J Cancer       Date:  2012-02-14       Impact factor: 7.640

7.  Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.

Authors:  C Tekle; E Giovannetti; J Sigmond; J R Graff; K Smid; G J Peters
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.